Haisco(SZ:002653)2023-04-17 16:00Financial Performance - The company's operating revenue for 2022 was CNY 3,015,294,339.82, representing an increase of 8.73% compared to CNY 2,773,314,884.86 in 2021[12]. - The net profit attributable to shareholders for 2022 was CNY 277,002,781.63, a decrease of 19.72% from CNY 345,058,649.45 in 2021[12]. - The net profit after deducting non-recurring gains and losses was CNY 95,553,398.52, which is a significant increase of 171.42% compared to CNY 35,205,086.23 in 2021[12]. - The basic earnings per share for 2022 was CNY 0.26, down 18.75% from CNY 0.32 in 2021[12]. - The total assets at the end of 2022 were CNY 6,045,955,274.42, an increase of 20.79% from CNY 5,005,285,084.31 at the end of 2021[12]. - The net assets attributable to shareholders at the end of 2022 were CNY 3,035,744,121.70, reflecting a growth of 6.82% from CNY 2,841,929,513.83 at the end of 2021[12]. - The company reported a significant increase in cash flow from operating activities, with a net cash flow of CNY 94,546,036.93, up 164.08% from CNY 35,801,459.91 in 2021[12]. - The company achieved a revenue of 3.015 billion yuan in 2022, an increase of 8.73% year-on-year, while the net profit attributable to shareholders decreased by 19.72% to 277 million yuan[36]. Market and Product Development - The company is focusing on innovation in drug development, with an increase in the number of IND and NDA applications over the past five years[19]. - The company is committed to expanding its market presence and enhancing its product offerings in response to evolving industry dynamics[19]. - The company is actively advancing the international clinical trial of its anesthetic drug HSK3486 in the United States[22]. - The company has submitted NDA for its diabetes peripheral neuropathy drug HSK16149 and type 2 diabetes treatment drug HSK7653, which are currently under review[22]. - The company is recognized as one of the top 100 Chinese pharmaceutical companies and has achieved an AAA credit rating in the pharmaceutical industry[22]. - The company is focused on providing innovative specialty drugs across various therapeutic areas, including anesthesia, oncology, and cardiovascular health[23]. - The company has established a comprehensive marketing innovation system focused on patient-centered and academic marketing, with eight major business divisions[28]. - The company has established multiple technical platforms for drug development, including platforms for poorly soluble formulations and inhalation formulations[35]. Research and Development - The company has a research and development team of over 900 personnel, with approximately 37% holding master's degrees or higher, and a high proportion of PhD holders in core departments reaching 60%[33]. - The company has undertaken 6 national-level major scientific research projects, including the clinical research of the new GABAA receptor agonist HSK3486 and innovative research on new drugs for AIDS and hepatitis B prevention[32]. - The R&D team has published nearly 40 papers in core journals, focusing on fields such as anesthesia analgesia and diabetes[32]. - The company has a strong pipeline with multiple products in various stages of clinical trials, enhancing its competitive edge[57]. - R&D investment reached approximately 958 million yuan in 2022, with expectations for further growth in 2023 to support the introduction of innovative drug products[118]. Governance and Management - The company has implemented a comprehensive governance structure, ensuring compliance with relevant laws and regulations, and enhancing operational efficiency[86]. - The company has established independent personnel management systems and signed labor contracts with employees, ensuring no interference from controlling shareholders[88]. - The company has a diverse board with members holding positions in various other organizations, including independent directors and executives in different sectors[97][98]. - The company emphasizes a performance-based salary structure for its senior management, which is reviewed and adjusted annually[99]. - The company has established a robust governance structure with a mix of experienced professionals from various sectors, ensuring comprehensive oversight and strategic guidance[97][98]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities, adhering to various environmental standards and regulations[129]. - The company achieved a total emission of 0.515 tons of particulate matter, which is below the approved limit of 3.34 tons[134]. - The company has obtained environmental impact assessment approvals for projects in Liaoning, Sichuan, and Shenyang, with specific registration numbers issued in July 2022[132]. - The company has implemented wastewater treatment measures that ensure all discharges meet or exceed local environmental standards, reflecting a commitment to sustainability[135]. - The company is actively monitoring and managing its emissions to align with regulatory requirements and improve environmental performance[136]. Social Responsibility - The company actively participated in social welfare activities, including donations to special education schools and support for frontline police officers, totaling over 10,000 yuan in various contributions[149]. - The company plans to invest 120 million yuan in a new chemical drug production base in Shannan City, Tibet, which is expected to create over 100 jobs for local farmers and students[150]. - The company provided 1,000 square meters of office space for free to support entrepreneurship for impoverished university students in Shannan City[150]. - The company emphasizes the protection of employee rights and has established a comprehensive compensation and benefits management system to ensure fair treatment and a harmonious labor relationship[149]. Future Outlook - The company plans to apply for IND for 3-4 innovative drugs, including those in oncology and analgesia fields, while also launching 5-10 new projects[77]. - The company aims to become the most trusted international pharmaceutical enterprise, focusing on "R&D + marketing" dual-driven strategy and expanding market presence with innovative drugs like HSK7653 and HSK16149[76]. - The company plans to distribute at least 20% of its distributable profits as cash dividends during profit distribution[155].